Targeting Protein Kinases in Blood Cancer: Focusing on CK1α and CK2.
Ontology highlight
ABSTRACT: Disturbance of protein kinase activity may result in dramatic consequences that often lead to cancer development and progression. In tumors of blood origin, both tyrosine kinases and serine/threonine kinases are altered by different types of mutations, critically regulating cancer hallmarks. CK1α and CK2 are highly conserved, ubiquitously expressed and constitutively active pleiotropic kinases, which participate in multiple biological processes. The involvement of these kinases in solid and blood cancers is well documented. CK1α and CK2 are overactive in multiple myeloma, leukemias and lymphomas. Intriguingly, they are not required to the same degree for the viability of normal cells, corroborating the idea of "druggable" kinases. Different to other kinases, mutations on the gene encoding
SUBMITTER: Spinello Z
PROVIDER: S-EPMC8038136 | biostudies-literature | 2021 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA